Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories
-
Klotho Neurosciences (KLTO) Raises Over $11 Million, Retires All Debt, And Exceeds Nasdaq Stockholders' Equity Requirement
-
VivoPower (VVPR) and BitGo Partner to Facilitate its Initial $100M XRP Acquisition for Treasury Strategy
-
BitGo Enters Strategic Partnership with VivoPower (VVPR) to Facilitate its Initial US$100 Million XRP Acquisition for Treasury Strategy
-
BitGo Enters Strategic Partnership with VivoPower to Facilitate its Initial US$100 Million XRP Acquisition for Treasury Strategy
-
Classover Holdings (KIDZ) Completes Initial SOL Purchase and Enters into New Purchase Agreement to Sell up to $500M of Notes
-
Classover Completes Initial SOL Purchase and Enters into New Purchase Agreement to Sell up to $500 Million of Notes to Accelerate SOL Treasury Strategy
-
VivoPower (VVPR) Announces XRP-Focused Digital Asset Treasury Strategy and US$121 Million Private Placement Priced at US$6.05 Per Share
-
VivoPower Announces XRP-Focused Digital Asset Treasury Strategy and US$121 Million Private Placement Priced at US$6.05 Per Share, Above Last Market Closing Price Under NASDAQ Rules
-
Chardan Capital Markets Assumes CleanSpark Inc. (CLSK) at Buy
-
Prime Medicine (PRME) PT Lowered to $12 at Chardan Capital Markets
-
Chardan Capital Markets Reiterates Buy Rating on CervoMed (CRVO)
-
AB Science reports its revenues for the year 2024 and provides an update on its activities
-
Chardan Capital Markets Downgrades Seres Therapeutics (MCRB) to Neutral
-
Chardan Capital Markets Starts Bright Minds Biosciences Inc. (DRUG) at Buy
-
Chardan Capital Markets Starts Praxis Precision Medicines Inc. (PRAX) at Buy
-
Chardan Capital Markets Starts Xenon Pharmaceuticals (XENE) at Buy
-
iBio, Inc. (IBIO) Raises $6.2M Through Warrant Inducement Transaction
-
iBio Raises $6.2 Million Through Warrant Inducement Transaction
-
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
-
Chardan Capital Markets Starts Tourmaline Bio (TRML) at Buy
-
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
-
/C O R R E C T I O N -- Marcum Asia CPAs LLP/
-
Japan Go IPO Summit Announces Roster of Expert Speakers for Event June 5th in Tokyo
-
Chardan Capital Markets Starts Korro Bio Inc. (KRRO) at Buy
-
Kodiak to Go Public Via Business Combination With Ares Acquisition Corporation II (AACT)
-
Kodiak, a Leading Provider of AI-Powered Autonomous Vehicle Technology, to Go Public Via Business Combination With Ares Acquisition Corporation II
-
Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
-
Centri Announces Sponsors for Capital Conference at Nasdaq on April 22
-
Chardan Capital Markets Starts Palvella Therapeutics (PVLA) at Buy
-
Chardan Capital Markets Assumes uniQure BV (QURE) at Buy, PT $38
-
Chardan Capital Markets Reiterates Neutral Rating on Allurion Technologies (ALUR)
-
Zura Bio Ltd. (ZURA) PT Lowered to $10 at Chardan Capital Markets
-
Japan Go IPO Summit Provides Roadmap for Japanese Companies Seeking to List on U.S. Exchanges
-
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
-
Prime Medicine (PRME) PT Lowered to $16 at Chardan Capital Markets
-
Vincerx Pharma (VINC) Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
-
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
-
Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN)
-
Chardan Capital Markets Upgrades CervoMed (CRVO) to Buy
-
Passage Bio Inc. (PASG) PT Lowered to $6 at Chardan Capital Markets
-
Instinct Brothers to Go Public via Merger with Relativity Acquisition Corp (BIOT)
-
Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.
-
Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.
-
Dragonfly Energy Holdings (DFLI) Announces Corporate Debt Restructuring and Capital Raise
-
Dragonfly Energy Announces Corporate Debt Restructuring and Capital Raise
-
Urgently Announces Capital Structure Improvements and Secures up to $20 Million in New Financing
-
Senti Biosciences (SNTI) Strengthens Leadership Team with Strategic Hires
-
Senti Bio Strengthens Leadership Team with Strategic Hires
-
Eyenovia Inc (EYEN) Announces Debt Restructuring Including Amendment to Senior Secured Debt
-
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
